Biotechnology News and Research

RSS

Baxter licenses Vero cell-based influenza vaccine technology to Takeda

Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.

From Baxter International Inc. 2 Dec 2010

Biomagnetics identifies second biomarker for tuberculosis assay

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced the identification of a second biomarker for development of a tuberculosis assay.

2 Dec 2010

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases.

2 Dec 2010

Genzyme sells genetics business to LabCorp for $925M

Genzyme Corporation today announced that it has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings (NYSE: LH) for $925 million in cash.

2 Dec 2010

Oncolytics initiates enrollment in Phase II ovarian cancer study

Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

2 Dec 2010

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

Oramed Pharmaceuticals Inc. a developer of oral drug delivery solutions, announces a publication in the Journal of Diabetes Science and Technology's November issue describing evaluation of the company's glucagon-like peptide- (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.

2 Dec 2010

EHSI completes Celulas Genetica acquisition

Emerging Healthcare Solutions, Inc. today announced its acquisition of Celulas Genetica, a biotechnology firm based in Panama.

2 Dec 2010

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.

2 Dec 2010

Medical, socioeconomic, and gender-based factors impact global women's health issues

Access to quality reproductive healthcare for women around the globe is a fundamental aspect of a woman's human rights, freedom, equity, and right to control her own body. A Special Section on Global Women's Reproductive Health in the current issue of Journal of Women's Health, a peer-reviewed publication published by Mary Ann Liebert, Inc., explores the compelling medical, socioeconomic, and gender-based factors that impact global women's health issues. The Special Focus articles are available free online.

1 Dec 2010

Debiopharm recognised with European Biopharmaceuticals company of the year award

The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group™ (Debiopharm).

1 Dec 2010

Accelerator announces Series A Preferred Stock financing of Acylin

Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.

1 Dec 2010

Teva board authorizes $1 billion share repurchase program

Teva Pharmaceutical Industries Ltd. announced today that its Board of Directors has authorized the Company to repurchase (including through one or more subsidiaries) up to an aggregate of $1 billion of its ordinary shares/ADRs over the next 12 months.

1 Dec 2010

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon's comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.

1 Dec 2010

PhRMA reports 100 new medicines and vaccines in development for HIV/AIDS

America's biopharmaceutical research companies are working on 100 new medicines and vaccines [video] to treat and prevent HIV/AIDS and related conditions, according to a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA).

1 Dec 2010

Array BioPharma achieves $10 million clinical research milestone in Celgene collaboration

Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.

1 Dec 2010

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has begun Phase 1/2a clinical testing with its lead compound, Glymera(PB1023), in patients with Type 2 diabetes.

1 Dec 2010

ACT files IND application to initiate Phase I/II study for Dry AMD

Advanced Cell Technology, Inc. announced today that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).

30 Nov 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the initiation of a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.

30 Nov 2010

Biotechnology News and Research

Baxter licenses Vero cell-based influenza vaccine technology to Takeda

Biomagnetics identifies second biomarker for tuberculosis assay

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

Genzyme sells genetics business to LabCorp for $925M

Oncolytics initiates enrollment in Phase II ovarian cancer study

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

EHSI completes Celulas Genetica acquisition

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

Medical, socioeconomic, and gender-based factors impact global women's health issues

Debiopharm recognised with European Biopharmaceuticals company of the year award

Accelerator announces Series A Preferred Stock financing of Acylin

Teva board authorizes $1 billion share repurchase program

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

PhRMA reports 100 new medicines and vaccines in development for HIV/AIDS

Array BioPharma achieves $10 million clinical research milestone in Celgene collaboration

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

ACT files IND application to initiate Phase I/II study for Dry AMD

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Scientists identify signaling pathway and receptor for thymosin beta 4

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News